<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00431704</url>
  </required_header>
  <id_info>
    <org_study_id>VinCaT</org_study_id>
    <secondary_id>2006-003994-28</secondary_id>
    <nct_id>NCT00431704</nct_id>
  </id_info>
  <brief_title>VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer</brief_title>
  <acronym>VinCaT</acronym>
  <official_title>Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the activity and safety of the combination of
      vinorelbine, carboplatin and trastuzumab in HER2-positive metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The addition of trastuzumab to chemotherapy containing anthracyclines or taxanes has improved
      survival in patients with Her-2 positive metastatic breast cancer, but newer combinations
      with less toxicity and cross resistance are needed. Early clinical studies have suggested
      that the combination of vinorelbine, carboplatin and trastuzumab can be active against
      metastatic breast cancer, with less toxicity. In this phase II single center trial, 39
      patients will be enrolled to evaluate the activity and safety of this combination.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>after 3 and 6 cycles of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>after every cycle of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>at 12 months, end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>at 12 months, end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>vinorelbine, carboplatin, trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
    <description>25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients</description>
    <arm_group_label>vinorelbine, carboplatin, trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients</description>
    <arm_group_label>vinorelbine, carboplatin, trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression</description>
    <arm_group_label>vinorelbine, carboplatin, trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of breast cancer

          -  Stage IV disease

          -  None or at most one prior treatment for metastatic disease (prior treatment with
             trastuzumab for metastatic disease is not permitted)

          -  Overexpression of HER-2 (immunohistochemistry 3+) or genetic amplification of
             c-erbB2/neu (FISH+)

          -  ECOG Performance Status 0-2

          -  Age &gt;18 and &lt; 75 years

          -  Left Ventricular Ejection Fraction (LVEF) &gt;50%

          -  Life expectancy &gt;3 months

          -  Signed informed consent

        Exclusion Criteria:

          -  Absence of measurable or evaluable disease

          -  Life expectancy &lt; 3 months

          -  ECOG performance status &gt; 2

          -  History of prior malignancy in the last 5 years (other than adequately treated
             non-melanoma skin cancer or excised cervical carcinoma in situ).

          -  Previous chemotherapy with vinorelbine or carboplatin (as adjuvant therapy or for
             metastatic disease)

          -  Previous therapy with trastuzumab for metastatic disease (previous adjuvant therapy
             with trastuzumab is permitted)

          -  Neutrophil &lt; 2000/mm3, platelets &lt; 100,000/mm3, haemoglobin &lt; 9 g/dl

          -  Creatinine &gt; 1.5 x the upper normal limits

          -  GOT and/or GPT &gt; 2.5 x the upper normal limits and/or Bilirubin &gt; 1.5 x the upper
             normal limits in absence of hepatic metastases

          -  GOT and/or GPT &gt; 5 x the upper normal limits and/or Bilirubin &gt; 3 x the upper normal
             limits in presence of hepatic metastases

          -  Congestive hearth failure or history of congestive heart failure, unstable angina
             pectoris even if it is medically controlled, myocardial infarction, clinically
             significant valve disease, uncontrolled arrhythmia

          -  Any concomitant pathology that would, in the investigator's opinion, contraindicate
             the use of the drugs in this study

          -  Male gender

          -  Pregnant or lactating women

          -  Refusal or incapacity to provide informed consent

          -  Inability to comply with follow up
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Matteis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Medical Oncology C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Clinical Trials Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2007</study_first_submitted>
  <study_first_submitted_qc>February 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2007</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced</keyword>
  <keyword>her-2 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

